The dissident slate proposed by hostile bidder Axcan Pharma Inc. will probably not be elected at Salix Pharmaceuticals Ltd.’s annual meeting this Thursday, June 19. And Axcan’s general counsel implied that Axcan is ready to move on.
To read the entire story, you must be logged in.
Please log in now or register with us.
